Xenon Pharmaceuticals (XENE) Other Operating Expenses (2014 - 2026)

Xenon Pharmaceuticals (XENE) has 6 years of Other Operating Expenses data on file, last reported at $76.5 million in Q1 2026.

• On a quarterly basis, Other Operating Expenses rose 377.18% year-over-year to $76.5 million in Q1 2026; TTM through Mar 2026 was -$61.4 million, a 85.07% increase from a year earlier, with the FY2025 full-year figure at -$119.3 million, down 14.89% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $76.5 million, up from -$101.0 million in the prior quarter.
• Over the last five years, Other Operating Expenses for XENE reached as high as $98.5 million in Q4 2022 and fell as low as -$229.8 million in Q4 2024.
• Historically, Other Operating Expenses has averaged -$37.9 million across 4 years, with a median of -$28.9 million in 2025.
• Across the five-year window, Other Operating Expenses tumbled 463.42% in 2025 and jumped 377.18% in 2026, its largest moves.
• Year by year, Other Operating Expenses stood at $98.5 million in 2022, then slumped by 333.35% to -$229.8 million in 2024, then jumped by 56.05% to -$101.0 million in 2025, then soared by 175.74% to $76.5 million in 2026.
• Per Business Quant data, the three most recent Other Operating Expenses figures were $76.5 million in Q1 2026, -$101.0 million in Q4 2025, and -$6.7 million in Q3 2025.